These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 29393385)

  • 1. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
    Lian G; Li L; Shi Y; Jing C; Liu J; Guo X; Zhang Q; Dai T; Ye F; Wang Y; Chen M
    Int J Oncol; 2018 Mar; 52(3):804-814. PubMed ID: 29393385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells.
    Chen Z; Chai Y; Zhao T; Li P; Zhao L; He F; Lang Y; Qin J; Ju H
    J Cell Physiol; 2019 May; 234(5):5904-5914. PubMed ID: 30488440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma.
    Wu M; Wang Y; Yang D; Gong Y; Rao F; Liu R; Danna Y; Li J; Fan J; Chen J; Zhang W; Zhan Q
    EBioMedicine; 2019 Mar; 41():244-255. PubMed ID: 30876762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
    Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD
    World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
    Choi M; Kim W; Cheon MG; Lee CW; Kim JE
    Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
    Kadletz L; Bigenzahn J; Thurnher D; Stanisz I; Erovic BM; Schneider S; Schmid R; Seemann R; Birner P; Heiduschka G
    Head Neck; 2016 Apr; 38 Suppl 1():E1918-25. PubMed ID: 26713885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of autophagy improves resistance and enhances sensitivity of gastric cancer cells to cisplatin.
    Hou G; Bai Y; Jia A; Ren Y; Wang Y; Lu J; Wang P; Zhang J; Lu Z
    Can J Physiol Pharmacol; 2020 Jul; 98(7):449-458. PubMed ID: 32058824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
    Jemaà M; Kifagi C; Serrano SS; Massoumi R
    Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
    Xu HB; Shen FM; Lv QZ
    Eur J Pharmacol; 2015 Dec; 769():1-7. PubMed ID: 26407653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
    Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
    Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway.
    Liu H; Li P; Li B; Sun P; Zhang J; Wang B; Jia B
    Tumour Biol; 2015 Mar; 36(3):1445-53. PubMed ID: 25547433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A; Hugle M; Fulda S
    Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
    Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
    Shao C; Ahmad N; Hodges K; Kuang S; Ratliff T; Liu X
    J Biol Chem; 2015 Jan; 290(4):2024-33. PubMed ID: 25505174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
    Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
    Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
    Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
    Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baicalein enhanced cisplatin sensitivity of gastric cancer cells by inducing cell apoptosis and autophagy via Akt/mTOR and Nrf2/Keap 1 pathway.
    Li P; Hu J; Shi B; Tie J
    Biochem Biophys Res Commun; 2020 Oct; 531(3):320-327. PubMed ID: 32800561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.